Despite intensive research, no drug has to date been approved for the management of NAFLD, and many clinical trials have failed, including some recent large phase 3 trials. This has in part to do with the complex disease pathophysiology, which is only partially unravelled(1). Furthermore, the disease is embedded in a set of metabolic drivers, creating an environment of metabolic and inflammatory stress.